Are there large prospective population studies planned for OncuraKit?

OncuraKit and Yenos Analytical are in commercial and clinical development. The NHS-Galleri trial (enrolling 140,000 participants in the UK to test Grail's Galleri) represents the kind of large prospective validation that the broader MCED field needs. Similar large-scale prospective studies for OncuraKit are a clinical development goal that requires substantial funding and regulatory partnership. Currently, OncuraKit is available as an LDT to individuals, employers, and healthcare organizations who want proactive access to this science based on the existing published evidence. The ongoing commercial use of OncuraKit generates real-world data that will continue to build the evidence base. We actively collaborate with researchers interested in clinical validation partnerships — contact us at partners@oncura.health.